

Cystic Fibrosis Transmembrane Conductance Regulator Degradation Depends on the Lectins Htm1p/EDEM and the Cdc48 Protein Complex in Yeast

Andreas Gnann,* John R. Riordan,[†] and Dieter H. Wolf*[‡]

*Institut für Biochemie, Universität Stuttgart, 70569 Stuttgart, Germany; and [†]Samuel C. Johnson Medical Research Center, Mayo Clinic Scottsdale, Scottsdale, AZ 85259

Submitted January 12, 2004; Revised May 13, 2004; Accepted June 8, 2004
Monitoring Editor: Peter Walter

Cystic fibrosis is the most widespread hereditary disease among the white population caused by different mutations of the apical membrane ATP-binding cassette transporter cystic fibrosis transmembrane conductance regulator (CFTR). Its most common mutation, $\Delta F508$, leads to nearly complete degradation via endoplasmic reticulum-associated degradation (ERAD). Elucidation of the quality control and degradation mechanisms might give rise to new therapeutic approaches to cure this disease. In the yeast *Saccharomyces cerevisiae*, a variety of components of the protein quality control and degradation system have been identified. Nearly all of these components share homology with mammalian counterparts. We therefore used yeast mutants defective in the ERAD system to identify new components that are involved in human CFTR quality control and degradation. We show the role of the lectin Htm1p in the degradation process of CFTR. Complementation of the *HTM1* deficiency in yeast cells by the mammalian orthologue EDEM underlines the necessity of this lectin for CFTR degradation and highlights the similarity of quality control and ERAD in yeast and mammals. Furthermore, degradation of CFTR requires the ubiquitin protein ligases Der3p/Hrd1p and Doa10p as well as the cytosolic trimeric Cdc48p-Ufd1p-Npl4p complex. These proteins also were found to be necessary for ERAD of a mutated yeast "relative" of CFTR, Pdr5*_p.

INTRODUCTION

The endoplasmic reticulum (ER) is responsible for folding, modification, and delivery of secretory proteins to their site of action (Glick, 2002; Haigh and Johnson, 2002). It contains a highly active protein quality control system (QC), which scans the folding process of secretory proteins and retains those species that are unable to fold (Ellgaard and Helenius, 2003). They are eliminated by a process called ER-associated degradation (ERAD) via the ubiquitin proteasome system (Kostova and Wolf, 2003). Malfunction of these processes is the cause of many diseases (Kostova and Wolf, 2002; Rutishauser and Spiess, 2002). One of the most common hereditary diseases among the white population that is directly linked to QC and ERAD is cystic fibrosis (Kerem *et al.*, 1989; Riordan *et al.*, 1989). Here, a mutated ATP-binding cassette (ABC) transporter and chloride channel of the apical membrane, the cystic fibrosis transmembrane conductance regulator (CFTR) is recognized by the QC as being misfolded and degraded via the ubiquitin-proteasome system. The most frequent mutation of CFTR that causes this effect is the deletion of a phenylalanine at position 508 in the first nucleotide binding domain ($\Delta F508$). Interestingly even wild-type CFTR is very unstable and shows a degradation rate of ~70% (Ward and Kopito, 1994; Jensen *et al.*, 1995). It is important to note that $\Delta F508$ CFTR can still function as a chloride channel (Dalemans *et al.*, 1991) but due to QC and

ERAD, it fails to be transported to the apical plasma membrane. This could be overcome by lower temperature (Denning *et al.*, 1992), high glycerol (Sato *et al.*, 1996), or 4-phenylbutyrate (Rubenstein and Zeitlin, 2000). Because none of these treatments are of therapeutic value, other means have to be found to promote transport of mature $\Delta F508$ CFTR to the plasma membrane. Elucidation of the components of QC and ERAD that are responsible for the elimination of $\Delta F508$ CFTR is an important step in this direction. They may become targets for specific therapeutic manipulations to lead mutated but active CFTR to the cell surface. Previous studies have shown that the lectin calnexin interacts with CFTR in the ER lumen (Pind *et al.*, 1994). Furthermore the bidirectional Sec61 translocon of the ER membrane was suggested to contribute to QC and ERAD (Bebök *et al.*, 1998) as well as the cytosolic chaperones heat-shock protein Hsp70/Hsc70, Hsp90, and the cochaperone CHIP (Yang *et al.*, 1993; Loo *et al.*, 1998; Meacham *et al.*, 1999; Meacham *et al.*, 2001).

Cellular QC and ERAD are highly conserved mechanisms from yeast to human (Kostova and Wolf, 2002, 2003; Ellgaard and Helenius, 2003). The ready availability of yeast mutants defective in QC and ERAD makes this organism a preferred model for investigation of these processes. Indeed, the expression of CFTR in *Saccharomyces cerevisiae* has proven that the yeast components of QC and ERAD recognize this protein and degrade it via the proteasome in a ubiquitin-dependent manner (Kiser *et al.*, 2001; Zhang *et al.*, 2001). These studies have uncovered the yeast ubiquitin-conjugating enzymes Ubc6p and Ubc7p as well as the cytosolic Hsp70 as necessary components for the degradation of CFTR. Influence of the ubiquitin protein ligase Der3p/Hrd1p in CFTR degradation is somewhat controversial (Kiser *et al.*, 2001; Zhang *et al.*, 2001). Recently, the mammalian counterparts of yeast Ubc6p, Ubc7p, and Der3p/Hrd1p have been identified (Fang *et al.*, 2001; Tiwari and

Article published online ahead of print. Mol. Biol. Cell 10.1091/mbc.E04-01-0024. Article and publication date are available at www.molbiolcell.org/cgi/doi/10.1091/mbc.E04-01-0024.

[‡] Corresponding author. E-mail address: dieter.wolf@po.uni-stuttgart.de.

Table 1. Yeast strains used in this study

Strain	Genotype	Reference
W303-1B	<i>Matα ade2-1 ura3-1 trp1-1 leu2-3, 112 his3-11, 15 can1-100</i>	Chiang and Schekman, 1991
W303 WTCF	W303-1B [PDR5-human WT CFTR-URA3]	This study
W303 Δ CF	W303-1B [PDR5-human Δ F508 CFTR-URA3]	This study
YWO 500	MAT α PDR1-3 <i>ura3-1 trp1-1 leu2-3, 112 his 3-11, 15</i>	Mahé <i>et al.</i> , 1996
YAG 123	YWO500 [PDR5-human WT CFTR-URA3]	This study
YAG 124	YWO500 [PDR5-human Δ F508 CFTR-URA3]	This study
GKY 356	PDR1-3-LEU2 <i>leu2 ura3</i> [PDR5-human WT CFTR-URA3]	Kiser <i>et al.</i> , 2001
GKY 360	PDR1-3-HIS3 <i>his3 leu2 ura3 ubc6Δ/ubc7Δ::LEU2</i> [PDR5-human WT CFTR-URA3]	Kiser <i>et al.</i> , 2001
YAG 129	YWO500 Δ <i>htm1::kanMX</i> [PDR5-human WT CFTR-URA3]	This study
YAG 171	YWO500 Δ <i>htm1::kanMX</i> [PDR5-human WT CFTR-URA3/p413 TEF]	This study
YAG 172	YWO500 Δ <i>htm1::kanMX</i> [PDR5-human WT CFTR-URA3/p413 TEF-mEDEM-HA]	This study
YAG 174	YWO500 Δ <i>htm1::kanMX</i> [PDR5-human WT CFTR-URA3/p423 TEF-mEDEM-HA]	This study
YAG 198	YWO500 Δ <i>htm1::kanMX</i> [HA- <i>pdα5-26-LEU2</i> /p423 TEF]	This study
YAG 199	YWO500 Δ <i>htm1::kanMX</i> [HA- <i>pdα5-26-LEU2</i> /p423 TEF-mEDEM-HA]	This study
YAG 182	W303 Δ <i>prc1::LEU2</i> Δ <i>htm1::kanMX</i> [pRS316- <i>prc1-1-URA3</i> /p423 TEF]	This study
YAG 183	W303 Δ <i>prc1::LEU2</i> Δ <i>htm1::kanMX</i> [pRS316- <i>prc1-1-URA3</i> /p423 TEF-mEDEM-HA]	This study
YAG 60	MAT α PDR1-3-HIS3 <i>ura3-52 trp1-1 leu2-3 leu2-112 his3Δ200 lys2-801</i> [PDR5-human WT CFTR-URA3]	This study
YAG 61	MAT α PDR1-3-HIS3 <i>ura3-52 trp1-1 leu2-3 leu2-112 his3Δ200 lys2-801 Δ<i>hrd1::LEU2</i></i> [PDR5-human WT CFTR-URA3]	This study
YAG 58	MAT α PDR1-3-LEU2 <i>ura3-52 trp1-1 leu2-3 leu2-112 his3Δ200 lys2-801</i> [PDR5-human WT CFTR-URA3]	This study
YAG 59	MAT α PDR1-3-LEU2 <i>ura3-52 trp1-1 leu2-3 leu2-112 his3Δ200 lys2-801 Δ<i>doa10::HIS3</i></i> [PDR5-human WT CFTR-URA3]	This study
YAG 97	MAT α PDR1-3-TRP1 <i>ura3-52 trp1-1 leu2-3 leu2-112 his3Δ200 lys2-801 Δ<i>doa10::HIS3</i></i> Δ <i>hrd1::LEU2</i> [PDR5-human WT CFTR-URA3]	This study
YAG 153	PDR1-3-LEU2 <i>ade2 ura3 trp1-1 leu2-3 his3-11</i> [PDR5-human CFTR-URA3]	This study
YAG 154	PDR1-3-LEU2 <i>ade2 ura3 trp1-1 leu2-3 lys2-801 cdc48-1</i> [PDR5-human CFTR-URA3]	This study
YAG 184	<i>ade2 ura3 trp1-1 leu2-3 his3-11 Δ<i>pdα5::TRP1</i> [HA-<i>pdα5-26-LEU2</i>]</i>	This study
YAG 185	<i>ade2 ura3 trp1-1 leu2-3 lys2-801 cdc48-1 Δ<i>pdα5::TRP1</i> [HA-<i>pdα5-26-LEU2</i>]</i>	This study
YAG 192	MAT α PDR1-3-LEU2 <i>ade1-100 ura3-52 leu2-3 leu2-112 his4-519 Δ<i>pdα5::hisG</i></i> [PDR5-human WT CFTR-URA3]	This study
YAG 193	MAT α PDR1-3-LEU2 <i>ade1-100 ura3-52 leu2-3 leu2-112 his4-519 <i>ufd1-1</i> Δ<i>pdα5::hisG</i></i> [PDR5-human WT CFTR-URA3]	This study
YAG 188	MAT α <i>ade1-100 ura3-52 leu2-3 leu2-112 his4-519 Δ<i>pdα5::hisG</i> [HA-<i>pdα5-26-LEU2</i>]</i>	This study
YAG 189	MAT α <i>ade1-100 ura3-52 leu2-3 leu2-112 his4-519 <i>ufd1-1</i> Δ<i>pdα5::hisG</i> [HA-<i>pdα5-26-LEU2</i>]</i>	This study
YAG 208	YWO500 [PDR5-human WT CFTR-URA3/p413 TEF]	This study
YAG 209	YWO500 [HA- <i>pdα5-26-LEU2</i> /p423 TEF]	This study
YAG 210	W303 Δ <i>prc1::LEU2</i> [pRS316- <i>prc1-1-URA3</i> /p423 TEF]	This study

Weissman, 2001; Lenk *et al.*, 2002). Thus, *S. cerevisiae* proves to be an excellent model organism to further investigate the components of the QC and ERAD, which are required for the degradation of CFTR.

Mutants defective in newly discovered components of these processes have enabled testing of their involvement in CFTR degradation. These new experiments reveal that the ubiquitin protein ligases Der3p/Hrd1p and Doa10p seem to have a synergistic effect on the degradation of the CFTR protein. Furthermore, the cytosolic trimeric Cdc48-Ufd1-Npl4 complex is found to be crucially required for proteasomal elimination of the protein. In addition the QC and degradation process of CFTR is considerably disturbed in a mutant defective in the ER luminal lectin Htm1p. Most interestingly this defect can be complemented by the expression of the mammalian EDEM protein, showing that Htm1p and EDEM are functional homologues with respect to CFTR degradation.

MATERIALS AND METHODS

Construction and Growth Conditions of Yeast Strains

Standard procedures for genetic and molecular biological techniques and for media were carried out as described in Sambrook *et al.* (1989), Guthrie and Fink (1991), and Ausubel *et al.* (1992).

All *S. cerevisiae* strains used are listed in Table 1. Cells were grown at 25°C.

Strains YAG 153/YAG 154 (*CDC48/cdc48-1*) also were grown at the semipermissive temperature of 23°C in standard media. For CPY* (carboxy-peptidase yscY*) expression, cells were grown at 30°C, and starvation media for pulse-chase experiments contained only 0.1% glucose to induce CPY* expression.

Yeast strains were modified either by transformation with integrative or episomal plasmids, mating, and tetrad dissection or by deletion via PCR cassettes and homologous recombination (Wach *et al.*, 1994; Longtine *et al.*, 1998). The *cdc48-1* strain DBY 2030 originally created by K. U. Fröhlich (Fröhlich *et al.*, 1991) was crossed with strain W303-1B to obtain strains with suitable auxotrophy markers. *HTM1* was deleted in YWO 500 (Mahé *et al.*, 1996) by one step gene deletion (Wach *et al.*, 1994; Longtine *et al.*, 1998). The kanamycin deletion cassette with homologous sequences for the *HTM1* gene was amplified by PCR with the primers 5' HTM1 (5' gcgtaggataatctcttgacgg 3') and 3' HTM1 (5' ggcaccaggaaatggatgagctg 3'). Gene deletion was proven by kanamycin resistance and polymerase chain reaction (PCR) with primers Δ htm1 frw (5' ggcatctagatgtagcagc 3') and 3' kan (5' gaggcataaattccgtagcc 3') or 5' kan (5' cgagtcggaatcgagcagcc 3') and Δ htm1 rws (5' ttacccttaggaatagc 3').

All strains used for CFTR expression were modified with the PDR1-3 mutation. The PDR1-3 plasmids with LEU and HIS marker were from Kiser *et al.* (2001). In addition the PDR1-3 sequence was cloned into pRS 304 (*TRP*) (Sikorski and Hieter, 1989) via *ApaI/SacI* to obtain pAGC 28. Plasmids are summarized in Table 2. All three plasmids are of integrative nature. Before transformation pGK 122 and pAGC 28 were linearized with *NsiI*; pGK 121 with *HpaI*. Insertions were verified by prototroph selection and increased resistance against cycloheximide (CHX) on YPD plates (CHX resistance assay). Expression of the test proteins was done as described below.

CFTR Expression

CFTR was expressed from a low copy yeast expression vector with PDR5 promoter and terminator (Kiser *et al.*, 2001). To increase the expression level

Table 2. Plasmids

Plasmid	Insert	Reference
pGK118	<i>PDR5</i> -human WT CFTR- <i>URA3</i>	Kiser <i>et al.</i> , 2001
pGK119	<i>PDR5</i> -human Δ F508 CFTR- <i>URA3</i>	Kiser <i>et al.</i> , 2001
pGK 121	<i>PDR1-3-HIS3</i>	Kiser <i>et al.</i> , 2001
pGK122	<i>PDR1-3-LEU2</i>	Kiser <i>et al.</i> , 2001
pAGC 28	<i>PDR1-3-TRP1</i>	This study
pAGC 10	Δ <i>pr5::hisG-URA3-hisG</i>	Mahe <i>et al.</i> , 1996
pAGC 19	Δ <i>pr5::TRP1</i>	Bissinger and Kuchler, 1994
pAGC 52	HA- <i>pr5-26-LEU2</i>	Bissinger and Kuchler, 1994
p413 TEF		Mumberg <i>et al.</i> , 1995
p423 TEF		Mumberg <i>et al.</i> , 1995
pAGC 54	p413 TEF mouse EDEM-HA	This study
pAGC 55	p423 TEF mouse EDEM-HA	This study
pCT 40	pRS316- <i>prc1-1-HA₃-URA3</i>	C. Taxis (Institut für Biochemie, Stuttgart, Germany)

of the protein a *PDR1-3* gain of function mutation was introduced by homologous recombination with an integrative *PDR1-3* plasmid (Kiser *et al.*, 2001; this study). CFTR expression was proven by Western blotting and/or immunoprecipitation (IP). The antibody M3A7 (Kartner *et al.*, 1991) was used for Western and immunoprecipitation analysis.

PDR5 Deletion and *Pdr5***p* Expression

Wild-type *PDR5* was deleted by homologous recombination with plasmids either carrying a *TRP* or a *hisG-URA3-hisG* fragment flanked by *PDR5* sequence stretches (Bissinger and Kuchler 1994; Mahé *et al.*, 1996) as described in Rose *et al.* (1990). HA-*PDR5** (Bissinger and Kuchler, 1994; Egner *et al.*, 1998) was introduced on a centromeric plasmid by standard transformation (Soni *et al.*, 1993). Deletion and insertion were analyzed by Western blotting by using antibodies either against *Pdr5p* (Plemper *et al.*, 1998) for wild-type protein or against the N-terminal hemagglutinin (HA)-tag of the introduced HA-*Pdr5***p* (Babco, Berkeley, CA) and by CHX resistance assays.

CPY* Expression

A Δ *htm1*/ Δ *prc1* yeast strain was transformed with pCT 40 to obtain YAG 183. Expression of CPY* in pulse-chase experiments was induced with labeling media containing only 0.1% glucose. CPY antibodies were obtained from Molecular Probes (Eugene, OR).

CHX Resistance Assay

To show higher resistance of yeast cells carrying the *PDR1-3* gain of function mutation, CHX was added to YPD agar at concentrations of 0, 0.1, 0.25, 0.5, and 1 μ g/ml. The range was adjusted according to results of Carvajal *et al.* (1997). Cells were grown to an A_{600} of 1, washed in TE (50 mM Tris, pH 7.6, 1 mM EDTA), and 1 A_{600} of cells was taken up in 1 ml of TE. The cells were diluted 1:100 and 1:1000 in TE, and 3 μ l of both dilutions were spotted onto YPD-CHX plates and incubated at 30°C for 2 to 3 d until colonies were clearly visible. Cells that showed stronger resistance than the respective wild-type were picked for further tests and experiments.

Deletion of *PDR5* causes higher susceptibility to CHX. Δ *pr5* deletion strains stop growth under CHX treatment earlier than correlated *PDR5* wild-type strains. Used CHX concentrations were 0, 0.1, 0.25, and 0.5 μ g/ml according to Bissinger and Kuchler (1994).

Western Blotting of CFTR and *Pdr5***p*

Cells were grown in selective media at 25°C to an A_{600} of 1.2. ER membranes were isolated from 3 A_{600} of cells per sample. Cells were resuspended in 100 μ l of lysis buffer (50 mM Tris, pH 7.6, 1 mM EDTA) with protease inhibitor mix and broken with glass beads. Debris was removed by centrifugation at 3000 rpm, and membranes were sedimented at 13,000 rpm for 15 min at 4°C. Proteins were taken up in 50 μ l of urea sample buffer (8 M urea, 5% SDS, 200 mM Tris-HCl, pH 6.8, 0.1 mM EDTA, 1.5% dithiothreitol [DTT], 0.03% bromophenol blue), incubated for 30 min at room temperature (CFTR) or 15 min at 34°C (*Pdr5***p*), and 20 μ l of each sample were subjected to SDS-PAGE. Proteins were transferred to nitrocellulose membranes in a semidry blot at 90 mA for 90 min. Antibodies for detection were M3A7 or C-terminal CFTR antibody from R&D Systems (Minneapolis, MN) for CFTR and α N-1 (Plemper *et al.*, 1998) or α HA (Babco) for *Pdr5p* and HA-*Pdr5***p*, respectively. Proteins were visualized by enhanced chemiluminescence (ECL) detection (Amersham Biosciences UK, Little Chalfont, Buckinghamshire, United Kingdom) according to the manufacturer's instructions.

Pulse-Chase

For pulse-chase experiments of CFTR and *Pdr5***p*, cells were grown as for Western blotting and thereafter starved in sulfur-free media for 1–2 h. Subsequently, they were labeled for 30 min to 1 h with 20 μ Ci/ A_{600} ³⁵S-TRANS Label (ICN Biomedicals, Aurora, CA) in media lacking any nitrogen source and chased in standard CM media for 90–120 min. For CFTR and *Pdr5***p*, 3 A_{600} of cells per time point were lysed in breaking buffer (50 mM Tris, pH 7.6, 1 mM EDTA, protease inhibitors) by using glass beads by vortexing six times for 1 min each, followed by cooling down on ice for 1 min. For CFTR, 4 times concentrated cell solubilization buffer (4% SDS, 600 mM NaCl, 50 mM Tris, pH 7.5, protease inhibitors) was added to yield a concentration of 1. After addition of IP buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% DOC, 1% Triton X-100, protease inhibitors), insoluble material was centrifuged down at 13,000 rpm. The supernatant was incubated overnight with 2 μ l of M3A7 antibody at 4°C. M3A7 was precipitated with A/G Agarose (Oncogene Science, Boston, MA) and washed with RIPA (IP + 0.1% SDS). Protein was taken up in 2 times concentrated SDS sample buffer (125 mM Tris, pH 6.8, 20% glycerol, 2% SDS, 2% β -mercaptoethanol, 100 mM DTT, bromophenol blue) for 30 min at room temperature and transferred to 7% SDS-PAGE. Radioactive signals were quantified from dried gels with the PhosphorImager detection system (Molecular Dynamics, Sunnyvale, CA). The mean values of three to four experiments were taken to create the graphs.

For *Pdr5***p*, cell debris was removed after lysis, following the protocol from Plemper *et al.* (1998). Sedimented membranes were resuspended in IP buffer with 1% SDS and incubated on ice for 20 min. After addition of IP buffer without SDS containing 1.5 μ l of α HA, immunoprecipitation was carried out as with CFTR.

CPY* pulse-chase was carried out as described by Hiller *et al.* (1996) and Plemper *et al.* (1999). Briefly cells were grown logarithmically in selective media and labeled for 20 min with [³⁵S]methionine (Amersham Biosciences UK). After addition of an excess of nonradioactive methionine, samples were taken at the indicated time points, followed by cell disruption, immunoprecipitation, and SDS-PAGE. Quantification was carried out as described for CFTR.

Expression of Mouse EDEM (mEDEM)

Mouse EDEM cDNA carrying the sequence for a single HA-tag at the C-terminal end of the protein (Hosokawa *et al.*, 2001) was cloned into the low-copy and high-copy yeast expression vectors p413TEF and p423TEF (Mumberg *et al.*, 1995) via *SpeI/XhoI*. The plasmids were transformed into yeast cells by using standard methods (Soni *et al.*, 1993). Expression of mEDEM was verified by immunoblotting of yeast membrane fractions with HA antibodies (Babco).

RESULTS

CFTR Expression Is Temperature Dependent in Yeast Cells

CFTR is a polytopic transmembrane protein that is cotranslationally inserted into the ER membrane. Translocation into the membrane as well as its retrotranslocation into the cytosol for proteasomal degradation is thought to be mediated by the Sec61 complex in both mammalian and yeast cells (Bebök *et al.*, 1998; Kiser *et al.*, 2001). In mammalian cells, 70% of wild-type and 100% of Δ F508 CFTR is degraded by the proteasome after polyubiquitination (Jensen *et al.*, 1995; Ward *et al.*, 1995). In yeast, even the wild-type form of CFTR




Figure 1. Expression of human CFTR in yeast. A total of 3 A_{600} per time point were labeled with 20 $\mu\text{Ci}/A_{600}$ TRANS-Label. After cell lysis, protein was immunoprecipitated and detected as described under *Materials and Methods*. (A) Detectable expression levels of CFTR are dependent on the *PDR1-3* mutation. Wild-type CFTR (WT-CFTR) and mutated protein ($\Delta\text{F508-CFTR}$) were detected. The strain W303-1B was taken as a control without CFTR. (B) Yeast cells grown at different temperatures show decreasing CFTR expression with increasing temperatures. The highest amount of labeled CFTR was set to 100% for WT and ΔF508 CFTR independently.

is degraded to nearly 100% (Zhang *et al.*, 2001). There is no different degradation level of wild-type and mutant ΔF508 CFTR detectable in yeast (Zhang *et al.*, 2001). But, as in mammalian cells, CFTR is polyubiquitinated and degraded by the proteasome in yeast cells. Mutations in proteasomal genes or inhibition of the proteasome interferes with CFTR degradation (Kiser *et al.*, 2001; Zhang *et al.*, 2001).

For expression of human CFTR in yeast, we used the expression vector introduced by Kiser *et al.* (2001). The sequence of wild-type and ΔF508 CFTR was placed onto a low-copy yeast expression vector with promoter and terminator region of the yeast ABC transporter *Pdr5p* (Balzi *et al.*, 1994; Bissinger and Kuchler, 1994). As with *Pdr5p* levels, the introduction of a *PDR1-3* gain of function mutation (Carvajal *et al.*, 1997) increased the levels of CFTR protein to detectable amounts (Figure 1A). Because *Pdr5p* is reported to be induced at lower temperatures (Lashkari *et al.*, 1997) and CFTR can partially be stabilized at lower temperatures in cell culture (Denning *et al.*, 1992), we expressed the CFTR protein in cells growing in liquid media at 25, 30, and 37°C. As expected, the level of detectable CFTR protein increased with decreasing temperature (Figure 1B). The half-life of CFTR was dependent on the strain background and varied between 40 and 70 min. As proof for the validity of our

analysis system, CFTR degradation was tested in a $\Delta\text{ubc6}/\Delta\text{ubc7}$ strain (GKY 360; Kiser *et al.*, 2001) deficient in the two ubiquitin-conjugating enzymes *Ubc6p* and *Ubc7p*. Just as observed previously, there was a substantial decrease in the rate of CFTR degradation (unpublished data). This confirms that the expression and detection systems used function reliably.


Quality Control of CFTR Requires the Lectin *Htm1/EDEM*

In mammalian cells, CFTR is known to be glycosylated at two positions, N894 and N900, in the ER lumen (Riordan *et al.*, 1989). The protein acquires these oligosaccharide chains in yeast as well (Kiser *et al.*, 2001). In mammalian and yeast cells, it has been shown that core glycosylation of carbohydrate-containing proteins plays an important role in the protein quality control process. Trimming of the three glucose residues by glucosidases I and II as well as cleavage of the mannose-9 residue by α -mannosidase I of the $\text{GlcNAc}_2\text{Man}_6\text{Glc}_3$ structure are critical for the recognition of a malformed protein and the timing of its removal (Helenius and Aebi, 2001; Kostova and Wolf, 2003). In addition lectins of the ER lumen have been found to be essential components of the folding and recognition process. Specifically, calnexin has been shown to be a partner in the folding process of glycosylated proteins (Molinari *et al.*, 2003; Oda *et al.*, 2003). Also, CFTR has been found to interact with calnexin in mammalian cells (Pind *et al.*, 1994). In contrast to mammalian calnexin, no such function has been reported for *Cne1p* the yeast orthologue (Knop *et al.*, 1996). Also, degradation of CFTR was not influenced by the absence of *Cne1p* in yeast (Zhang *et al.*, 2001).

Recently, a newly identified yeast lectin *Htm1p* as well as its mammalian counterpart *EDEM* have been reported to trigger glycoprotein degradation (Hosokawa *et al.*, 2001; Jakob *et al.*, 2001). The soluble glycoprotein *CPY** as well as the membrane substrates *Pdr5*^p* and *Stt3-7^p* but not unglycosylated *Sec61-2^p* were shown to be dependent on *Htm1p* function in yeast to different extents. Overexpression of mammalian *EDEM* accelerated degradation of a well known mammalian model substrate, mutated α 1-anti-trypsin (Hosokawa *et al.*, 2001).

We tested the influence of a *HTM1* deletion on CFTR degradation in yeast. As can be seen in Figure 2, absence of *Htm1p* significantly slows the degradation rate of CFTR, indicating that this lectin can indeed recognize a heterologous glycosylated protein. Confirmation of the involvement of the lectin *Htm1p/EDEM* in degradation of CFTR would be provided by complementation of the delayed degradation process by expression of mammalian *EDEM* in yeast. We therefore cloned *mEDEM* containing a C-terminal HA-tag (Hosokawa *et al.*, 2001) into the low- and high-copy yeast expression vectors *p413TEF* and *p423TEF* (Mumberg *et al.*, 1995). As can be seen, the protein could be heterologously expressed in yeast and analogous to mammalian cells, it was found in the membrane fraction (Figure 3). We tested the influence of *mEDEM* on CFTR degradation in the yeast Δhtm1 deletion strain YAG 174. Pulse-chase analysis revealed that *mEDEM* expressed from the low-copy vector *p413TEF* could indeed restore the Δhtm1 defect in CFTR degradation to wild-type levels. To see whether higher levels of *mEDEM* would further accelerate CFTR degradation in yeast, we overexpressed *mEDEM* from the high-copy expression vector *p423TEF-mEDEM* in the Δhtm1 deletion strain. Overexpression of *mEDEM* restored the Δhtm1 defect to the same extent as found with the *p413TEF-mEDEM* low copy construct (Figure 2).

Figure 2. Influence of the yeast lectin Htm1p and its mammalian orthologue mEDEM on the degradation of CFTR. The wild-type strain *HTM1* and the $\Delta htm1$ deletion strain carried the empty yeast expression vector p413TEF as a control. mEDEM was expressed in $\Delta htm1$ strains either from the low-copy expression plasmid p413TEF-mEDEM or the high-copy expression plasmid p423TEF-mEDEM. The $\Delta htm1$ deletion delays the degradation rate of CFTR. Expression of mEDEM either from the low- or high-copy plasmid in the $\Delta htm1$ strain restores the degradation rate of CFTR to wild-type levels. A total of 3 A_{600} cells per time point were labeled with 20 $\mu\text{Ci}/A_{600}$ TRANS-Label. Pulse-chases and quantification were done as described under *Materials and Methods*. Samples were separated by 7% SDS-PAGE and quantified with PhosphorImager cassettes. The protein quantity of time point $t = 0$ min was set to 100%. The graphs show average degradation rates of three experiments in wild-type (*HTM1* + p413TEF) and deletion strains ($\Delta htm1$) without (+ p413TEF) or with mEDEM (+ p413TEF-mEDEM/+ 423TEF-mEDEM) in a 90-min chase and average half life of CFTR protein. Error bars indicate the variations of the different experiments. As long as error bars do not overlap we can speak of statistically significant differences between the tested strains. The autoradiographs of 7% SDS gels show typical results.



EDEM and Yeast ERAD Substrates

We also tested the influence of mEDEM on the yeast ERAD substrates CPY* (*prc1-1*) and Pdr5**p* (*pdr5-26*) in $\Delta htm1$ strains. Our results revealed no significant complementing capacity of mEDEM in case of the two yeast substrates (Figure 4, A and B). Degradation of the polytopic CFTR yeast orthologue Pdr5**p* seems to be somewhat stimulated but is barely significant. No significant influence of mEDEM could be detected on the degradation of mutated soluble CPY*. Thus, mammalian EDEM seems to be specific for the mammalian protein CFTR.




Figure 3. Expression and membrane localization of mouse EDEM in yeast cells. mEDEM-HA was cloned into high (p423TEF) and low-copy (p413TEF) yeast expression vectors and expressed in a $\Delta htm1$ *PDR1-3* yeast strain carrying human CFTR. Cells were grown to an A_{600} of ~ 1.2 and lysed with glass beads. Membranes were separated from supernatant and solubilized in buffer containing SDS and Triton X-100. Samples were separated by SDS-PAGE and blotted on nitrocellulose. Immunodetection was carried out with HA antibodies (Babco) and ECL (Amersham Biosciences UK). The empty vector p413 TEF was taken as a control. The protein was solely detectable in pellet fractions (P). The supernatant (S) was clear.

E3 Enzymes in CFTR Ubiquitination

Polyubiquitination is a prerequisite for the degradation of ERAD substrates via the proteasome (Kostova and Wolf, 2003). This has been shown to be the case for CFTR as well (Jensen *et al.*, 1995; Ward *et al.*, 1995). In yeast cells, the E2 enzymes Ubc6p and Ubc7p were found to be required for polyubiquitination of CFTR (Kiser *et al.*, 2001; Zhang *et al.*, 2001). Recent data uncovered the involvement of the mammalian orthologue of yeast Ubc6p in the polyubiquitination process (Lenk *et al.*, 2002). The final step in ubiquitin coupling is mediated or directly carried out by ubiquitin-conjugating E3 enzymes. These enzymes are thought to have high substrate specificity. It has been shown that in mammalian cells CHIP (Meacham *et al.*, 2001) and SCF-FBX2 (Yoshida *et al.*, 2002) can function as E3 enzymes, which trigger degradation of CFTR to some extent. However, neither of these proteins seems to exhibit a very strong effect. This points to the fact that polyubiquitination of CFTR seems to be mediated by different E3s with overlapping specificity. Studies in yeast led to controversial results concerning the involvement of the well established E3 Der3p/Hrd1p in the degradation process (Kiser *et al.*, 2001; Zhang *et al.*, 2001). Recently, another ubiquitin-protein ligase, Doa10p, was found (Swanson *et al.*, 2001).

We carried out pulse-chase experiments by using mutant cells defective in the two E3 enzymes Der3p/Hrd1p and Doa10p and followed the degradation of CFTR. As can be seen in Figure 5, deletion of Der3p/Hrd1p or Doa10p leads to a slight but significant slow down of CFTR degradation in both single mutants. The double deletion of *DER3/HRD1* and *DOA10* results in a strong stabilization of CFTR, indicating considerable overlapping specificity of these two ubiquitin-conjugating enzymes with respect to CFTR recognition.

Degradation of CFTR Is Dependent on a Functional Cdc48 Complex

Very little is yet known how CFTR is delivered from the ER membrane to its final destination of degradation, the pro-




Figure 4. Influence of mEDEM on glycosylated yeast ERAD substrates in Δ *htm1* strains. Pulse-chase analysis was done as described in text. The graphs show average kinetics of three experiments of 90-min pulse-chases and average half-life in wild-type (*HTM1* + p423TEF) and Δ *htm1* deletion strains with (p423TEF-mEDEM) or without (p423TEF) mouse EDEM. Error bars indicate the variations of the different experiments. The autoradiographs show typical results. (A) Pdr5*p degradation shows a barely significant increase in a strain with mEDEM expression. (B) mEDEM does not show a significant increase of CPY* degradation.




Figure 5. E3 ubiquitin ligases Der3p/Hrd1p and Doa10p are involved in CFTR degradation. Pulse-chase analysis was carried out as described in text. The mean values of four experiments were taken to create the kinetics and half-life graphs of CFTR protein for each, wild-type (*HRD1/DOA10*) and deletion strains Δ *hrd1*, Δ *doa10* and the double deletion strain Δ *hrd1*/ Δ *doa10*. The autoradiographs show typical results.

teasome. Does the proteasome directly bind to the ER surface and tear the CFTR protein out of the membrane by virtue of its 19S cap ATPases or is the protein extracted via a chaperone-mediated mechanism? It has previously been shown that a trimeric complex in the cytosol consisting of the AAA ATPase Cdc48, Ufd1, and Npl4 is responsible for liberation of some misfolded proteins from the ER membrane (Bays *et al.*, 2001; Ye *et al.*, 2001; Braun *et al.*, 2002; Jarosch *et al.*, 2002; Rabinovich *et al.*, 2002; Chevalier and Johnson, 2003; Taxis *et al.*, 2003).

We therefore tested the involvement of this complex in the degradation of the polytopic CFTR protein as well as the mutated yeast orthologue Pdr5**p* by using *cdc48-1* (YAG 154) and *ufd1-1* (YAG 193) mutants. Wild-type and the cold-sensitive *cdc48-1* mutant strains (YAG 153; YAG 154) were grown at the permissive temperature of 25°C and the semi-permissive temperature of 23°C. As can be seen, the mutant strain showed a large reduction in the rate of degradation even at the permissive temperature, which was further increased at the semipermissive temperature of 23°C (Figure 6A). The half-life of CFTR was increased from 32 min in wild-type cells to 173 min in the mutant strain. In case of Pdr5**p*, the half-life increased from 42 min for wild-type and 131 min for *cdc48-1* cells (Figure 6B). Because the rate of degradation is comparable between both proteins, yeast does not seem to distinguish between endogenous and heterologously expressed proteins in the use of the AAA ATPase Cdc48. This result was verified in pulse-chase experiments by using mutants defective in a second component of the trimeric Cdc48 complex, Ufd1p. As expected in a *ufd1-1* mutant, CFTR as well as Pdr5**p* degradation was inhibited (Figure 7, A and B). The influence of the *ufd1-1* mutation on CFTR turnover was somewhat smaller than that of the *cdc48-1* mutation but still significant, whereas the effect of the *ufd1-1* mutation on Pdr5**p* degradation was comparable with that of the strain carrying the *cdc48-1* mutation. According to the proposed model which assigns the function of liberation of misfolded proteins from the ER to the trimeric Cdc48 complex (Bays *et al.*, 2001; Ye *et al.*, 2001; Braun *et al.*, 2002; Jarosch *et al.*, 2002; Rabinovich *et al.*, 2002), this function seems to hold true also for Pdr5**p* and the heterologously expressed CFTR protein.

DISCUSSION

Our studies revealed new insights into the degradation mechanism of human CFTR in yeast. By this, they

strengthen the previous findings that CFTR QC and ERAD can be examined reliably in the baker's yeast *S. cerevisiae*. Using yeast mutants, we studied the function of newly detected components of the QC and ERAD processes on the degradation of the polytopic CFTR chloride channel.

The determining factors that decide the fate of a protein between maturation and degradation are still mostly unknown. One new factor is the yeast lectin Htm1p and its mammalian orthologue EDEM. These lectins have been shown to accelerate specifically degradation of both soluble and membrane glycoproteins in yeast and mammalian cells, respectively. As shown here, deletion of yeast Htm1p has a significant effect on degradation of human CFTR. Most interestingly, this defect can be complemented by expression of mammalian EDEM in *HTM1*-deleted yeast cells. Both, low- and high-copy expression of mEDEM in a Δ *htm1* deletion strain restored the degradation of CFTR to *HTM1* wild-type levels. This shows that this pair of orthologous lectins is indeed an important component in the recognition and degradation process of CFTR. Unlike the findings in mammalian cells (Molinari *et al.*, 2003), overexpression of mEDEM in yeast cells did not show accelerated degradation levels compared with mEDEM expressed from a centromeric expression vector. This seems to indicate that the concentration of mEDEM expressed from the single copy vector is sufficient to bind all the available carbohydrate processed CFTR species generated in yeast.

In the case of the yeast orthologue Pdr5**p*, mEDEM restored the *HTM1* deficiency to a considerably lesser and barely significant extent. No effect was visible on soluble yeast CPY*. The lacking restoration ability of EDEM on the degradation of Pdr5**p* and CPY* in Htm1p-deficient cells may be due to different binding properties of the glycosylated yeast proteins to EDEM. At present, the precise reason for this functional specificity of mEDEM toward mammalian CFTR remains unknown.

Proteasomal degradation of misfolded proteins requires polyubiquitination via ubiquitin conjugating enzymes (E2s) and ubiquitin protein ligases (E3s). The latter class of enzymes is thought to provide the specificity of the degradation process. Two potential E3s from different classes have been reported to partially influence CFTR degradation in mammalian cells (Meacham *et al.*, 2001; Yoshida *et al.*, 2002). Neither had strong effects on the degradation process. It thus seems that E3s have broader overlapping function in the degradation of misfolded proteins requiring different




Figure 6. AAA ATPase Cdc48 is involved in both yeast and mammalian polytopic transmembrane protein degradation. With shift to starvation media, cells were grown at the semipermissive temperature of 23°C. A total of 3 A₆₀₀ per time point were labeled with 20 μCi/A₆₀₀ TRANS-Label. Pulse-chase experiments and CFTR quantification were done as described in text. (A) CFTR is strongly stabilized in a *cdc48-1* mutant. The graphs show average kinetics of four experiments of degradation in the 90-min pulse-chase and average half-life of CFTR in wild-type (*CDC48*) and mutant strains (*cdc48-1*). Error bars indicate the variations of the different experiments. The autoradiograph shows a typical result. (B) same as in A but for the mutated yeast ABC transporter protein Pdr5*p, which is also strongly stabilized.

enzymes to work in cooperation or independently. A well-known E3 from yeast is Der3p/Hrd1p. In yeast, it showed different levels of impact on the degradation of different substrates (Bordallo *et al.*, 1998; Plemper *et al.*, 1998; Wilhovsky *et al.*, 2000), including CFTR (Kiser *et al.*, 2001; Zhang *et al.*, 2001). Concerning CFTR expressed in yeast, the data were controversial. Therefore, we tested the effect of a *DER3/HRD1* deletion on CFTR degradation. We could detect a small but significant delay of degradation of the CFTR protein. The deletion of another newly discovered yeast E3, Doa10p, led to a similar stabilization of CFTR. A double deletion of *DER3/HRD1* and *DOA10* strongly increased the

stabilization of CFTR. This shows a cooperation of Hrd1p and Doa10p in CFTR ubiquitination. Because no complete stabilization of CFTR is found in the absence of the two enzymes tested, additional E3s involved in CFTR ubiquitination can be expected to be found. Alternatively, the contribution of additional nonproteasomal proteolytic systems cannot be excluded completely.

It had been speculated that the proteasomal ATPases might be involved in pulling CFTR from the ER and deliver it to the proteasome (Zhang *et al.*, 2001). Such an extracting function also has been suggested for a hybrid membrane protein by Mayer *et al.* (1998). Proteasomes have indeed been




Figure 7. An *ufd1-1* mutant strain shows significant slow down of CFTR and Pdr5*p degradation. Strains were treated as described in text. (A) The graphs show average kinetics of three experiments of degradation in the 100-min pulse-chase and average half-life of CFTR in wild-type (*UFD1*) and mutant strains (*ufd1-1*). Error bars indicate the variations of the different experiments. The autoradiograph shows a typical result. (B) Same as in A but for the mutated yeast ABC transporter protein Pdr5*p.

reported to be associated with the cytoplasmic surface of the ER membrane (Rivett *et al.*, 1992; Palmer *et al.*, 1996). However, if there were a direct extraction of proteins from the ER membrane by the proteasome one would not expect ubiquitinated proteins in the cytosol with blocked proteasomal activity as it had been shown for CPY* (Jarosch *et al.*, 2002) in yeast cells. Cytosolic accumulation of the protein also had been shown for MHC class I heavy chains in mammalian cells transfected with cytomegalovirus under these conditions (Wiertz *et al.*, 1996a, b). Furthermore, the formation of aggresomes in mammalian cells containing CFTR that can occur when proteasome activity is blocked (Johnston *et al.*, 1998; Wigley *et al.*, 1999; Chen *et al.*, 2000) would implicate an additional pulling force at the cytosolic surface of the ER

membrane. Recently, the function of the cytosolic trimeric AAA ATPase complex Cdc48-Ufd1-Npl4 had been shown to be responsible for liberation of a variety of ERAD substrates from the ER membrane (Bays *et al.*, 2001; Ye *et al.*, 2001; Braun *et al.*, 2002; Jarosch *et al.*, 2002; Rabinovich *et al.*, 2002; Chevalier and Johnson, 2003; Taxis *et al.*, 2003). Therefore, we tested the involvement of Cdc48p in the degradation process of CFTR by using respective mutants. Defective Cdc48p exhibited a dramatic effect on CFTR degradation, which was comparable to the degradation block of the orthologous yeast transmembrane transporter Pdr5*p. Also, a mutation in the Ufd1p component of the complex led to decreased degradation kinetics of CFTR and Pdr5*p. In summary, the function of the trimeric Cdc48 complex in libera-

tion of the CFTR protein from the ER is evident and supports a chaperone-mediated extraction from the ER membrane and delivery to the proteasome rather than a direct extraction by the ATPases of the 19S cap of the proteasome.

Finally, the data presented in this study demonstrate that the glycosylation of CFTR contributes to its quality control and degradation process. Ubiquitination by E3 enzymes does not exhibit the previously proposed substrate specificity but can be mediated by different enzymes probably with varying affinities. Before its degradation, CFTR is extracted from the ER membrane by involvement of the cytosolic trimeric Cdc48 complex rather than by the proteasome directly. The similarity of different QC and ERAD factors between yeast and mammalian cells is further supported by the direct complementation of yeast Htm1p by mEDeM and confirms the utility of yeast for further elucidation of biosynthetic processing of CFTR and related membrane proteins.

ACKNOWLEDGMENTS

We thank M. Gentsch for strains, plasmids, antibodies, and discussion; and K. U. Fröhlich and M. Hochstrasser for strains. We also acknowledge N. Hosokawa and K. Nagata for the kind gift of cDNA of mouse EDEM. This work has been supported by the Mukoviszidose e.V., the Deutsche Forschungsgemeinschaft, and the Bundesministerium für Bildung und Forschung (Deutsch-Israellische Projektkooperation) (all Bonn, Germany).

REFERENCES

Ausubel, F.M., Kingston, R.E., Seidman, F.G., Struhl, K., Moore, D.D., Brent, R., and Smith, F.A. (1992). *Current Protocols in Molecular Biology*, New York: Greene.

Balzi, E., Wang, M., Leterme, S., Van Dyck, L., and Goffeau, A. (1994). PDR5, a novel yeast multidrug resistance conferring transporter controlled by the transcription regulator PDR1*. *J. Biol. Chem.* 269, 2206–2214.

Bays, N.W., Wilhovsky, S.K., Goradia, A., Hodgkiss-Harlow, K., and Hampton, R.Y. (2001). HRD4/NPL4 is required for the proteasomal processing of ubiquitinated ER proteins. *Mol. Biol. Cell* 12, 4114–4128.

Braun, S., Matuschewski, A., Rape, M., Thoms, S., and Jentsch, S. (2002). Role of the ubiquitin-selective CDC48 (UFD1/NPL4) chaperone (segregase) in ERAD of OLE1 and other substrates. *EMBO J.* 21, 615–621.

Bebök, Z., Mazzochi, C., King, S.A., Hong, J.S., and Sorscher, E.J. (1998). The mechanism underlying cystic fibrosis transmembrane conductance regulator transport from the endoplasmic reticulum to the proteasome includes Sec61beta and a cytosolic, deglycosylated intermediary. *J. Biol. Chem.* 273, 29873–29878.

Bissinger, P.H., and Kuchler, K. (1994). Molecular cloning and expression of the *Saccharomyces cerevisiae* STS1 gene product. *J. Biol. Chem.* 269, 4180–4186.

Bordallo, J., Plemper, R.K., Finger, A., and Wolf, D.H. (1998). Der3p/Hrd1p is required for endoplasmic reticulum-associated degradation of misfolded luminal and integral membrane proteins. *Mol. Biol. Cell* 9, 209–222.

Carvajal, E., van den Hazel, H.B., Cybularz-Kolaczowska, A., Balzi, E., and Goffeau, A. (1997). Molecular and phenotypic characterization of yeast PDR1 mutants that show hyperactive transcription of various ABC multidrug transporter genes. *Mol. Gen. Genet.* 256, 406–415.

Chen, E.Y., Bartlett, M.C., and Clarke, D.M. (2000). Cystic fibrosis transmembrane conductance regulator has an altered structure when its maturation is inhibited. *Biochemistry* 39, 3797–3803.

Chevalier, M.S., and Johnson, D.C. (2003). Human cytomegalovirus US3 chimeras containing US2 cytosolic residues acquire major histocompatibility class I and II protein degradation properties. *J. Virol.* 77, 4731–4738.

Chiang, H.L., and Schekman, R. (1991). Regulated import and degradation of a cytosolic protein in the yeast vacuole. *Nature* 350, 313–318.

Dalemans, W., *et al.* (1991). Altered chloride ion channel kinetics associated with the Δ F508 cystic fibrosis mutation. *Nature* 354, 526–528.

Denning, G.M., Anderson, M.P., Amara, J.F., Marshall, J., Smith, A.E., and Welsh, M.J. (1992). Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. *Nature* 358, 761–764.

Egner, R., Rosenthal, F.E., Kralli, A., Sanglard, D., and Kuchler, K. (1998). Genetic separation of FK506 susceptibility and drug transport in the yeast Pdr5 ATP-binding cassette multidrug resistance transporter. *Mol. Biol. Cell* 9, 523–543.

Ellgaard, L., and Helenius, A. (2003). Quality control in the endoplasmic reticulum. *Nat. Rev. Mol. Cell. Biol.* 4, 181–191.

Fang, S., Ferrone, M., Yang, C., Jensen, J.P., Tiwari, S., and Weissman, A.M. (2001). The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in the degradation from the endoplasmic reticulum. *Proc. Natl. Acad. Sci. USA* 98, 14422–14427.

Fröhlich, K.U., Fries, H.W., Rudiger, M., Erdmann, R., Botstein, D., and Mecke, D. (1991). Yeast cell cycle protein CDC48p shows full-length homology to the mammalian protein VCP and is a member of a protein family involved in secretion, peroxisome formation, and gene expression. *J. Cell Biol.* 114, 443–453.

Glick, B.S. (2002). The secretory pathway. In: *Protein Targeting, Transport and Translocation*, ed. R.E. Dalbey and G. von Heijne, London: Academic Press, 358–376.

Guthrie, C., and Fink, G.R. (1991) *Guide to Yeast Genetics and Molecular Biology*, Vol. 194, New York: Academic Press.

Haigh, N.G. and Johnson, A.E. (2002) Protein sorting at the endoplasmic reticulum. In: *Protein Targeting, Transport and Translocation*, ed. R.E. Dalbey and G. von Heijne, London: Academic Press, 74–106.

Helenius, A., and Aebi, M. (2001). Intracellular functions of N-linked glycans. *Science* 291, 2364–2369.

Hiller, M.M., Finger, A., Schweiger, M., and Wolf, D.H. (1996). ER degradation of a misfolded luminal protein by the cytosolic ubiquitin-proteasome pathway. *Science* 273, 1725–1728.

Hosokawa, N., Wada, I., Hasegawa, K., Yorihozi, T., Tremblay, L.O., Herscovics, A., and Nagata, K. (2001). A novel ER α -mannosidase-like protein accelerates ER-associated degradation. *EMBO Rep.* 2, 415–422.

Jakob, C.A., Bodmer, D., Spirig, U., Bättig, P., Marcil, A., Dignard, D., Bergeron, J.J.M., Thomas, D.Y., and Aebi, M. (2001). Htm1p, a mannosidase-like protein, is involved in glycoprotein degradation in yeast. *EMBO Rep.* 2, 423–430.

Jarosch, E., Taxis, C., Volkwein, C., Bordallo, J., Finley, D., Wolf, D.H., and Sommer, T. (2002). Protein dislocation from the ER requires polyubiquitination and the AAA-ATPase Cdc48. *Nat. Cell Biol.* 4, 134–138.

Jensen, T.J., Loo, M.A., Pind, S., Williams, D.B., Goldberg, A.L., and Riordan, J.R. (1995). Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. *Cell* 83, 129–135.

Johnston, J.A., Ward, C.L., and Kopito, R.R. (1998). Aggresomes: a cellular response to misfolded proteins. *J. Cell Biol.* 143, 1883–1898.

Kartner, N., *et al.* (1991). Expression of the cystic fibrosis gene in non-epithelial invertebrate cells produces a regulated anion conductance. *Cell* 64, 681–691.

Kerem, B.-S., Rommens, J.M., Buchanan, J.A., Markiewicz, D., Cox, T.K., Chakravarti, A., Buchwald, M., and Tsui, L.-C. (1989). Identification of the cystic fibrosis gene, gene analysis. *Science* 245, 1073–1080.

Kiser, G.L., Gentsch, M., Kloser, A.K., Balzi, E., Wolf, D.H., Goffeau, A., and Riordan, J.R. (2001). Expression and degradation of the cystic fibrosis transmembrane conductance regulator in *Saccharomyces cerevisiae*. *Arch. Biochem. Biophys.* 390, 195–205.

Knop, M., Hauser, N., and Wolf, D.H. (1996). N-Glycosylation affects endoplasmic reticulum degradation of a mutated derivative of carboxypeptidase yscY in yeast. *Yeast* 12, 1229–1238.

Kostova, Z. and Wolf, D.H. (2002) Protein quality control in the export pathway, the endoplasmic reticulum and its cytoplasmic proteasome connection. In: *Protein Targeting, Transport and Translocation*, ed. R.E. Dalbey and G. von Heijne, London: Academic Press, 180–213.

Kostova, Z., and Wolf, D.H. (2003). For whom the bell tolls, protein quality control of the endoplasmic reticulum and the ubiquitin-proteasome connection. *EMBO J.* 22, 2309–2317.

Lashkari, D.A., DeRisi, J.L., McCusker, J.H., Namath, A.F., Gentile, C., Hwang, S.Y., Brown, P.O., and Davis, R.W. (1997). Yeast microarrays for genome wide parallel genetic and gene expression analysis. *Proc. Natl. Acad. Sci. USA* 94, 13057–13062.

Lenk, U., Yu, H., Walter, J., Gelman, M.S., Hartmann, E., Kopito, R.R., and Sommer, T. (2002). A role for mammalian Ubc6 homologues in ER-associated protein degradation. *J. Cell Sci.* 115, 3007–3014.

Longtine, M.S., McKenzie, A., III, Demarini, D.J., Shah, N.G., Wach, A., Brachat, A., Philippsen, P., and Pringle, J.R. (1998). Additional modules for

- versatile and economical PCR-based gene deletion and modification in *Saccharomyces cerevisiae*. *Yeast* 14, :953–961.
- Loo, M.A., Jensen, T.J., Cui, L., Hou, Y., Chang, X.B., and Riordan, J.R. (1998). Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. *EMBO J.* 17, 6879–6887.
- Mahé, Y., Lemoine, Y., and Kuchler, K. (1996). The ATP binding cassette transporters Pdr5 and Snq2 of *Saccharomyces cerevisiae* can mediate transport of steroids in vivo. *J. Biol. Chem.* 271, 25167–25172.
- Mayer, T.U., Braun, T., and Jentsch, S. (1998). Role of the proteasome in membrane extraction of a short-lived ER transmembrane protein. *EMBO J.* 17, 3251–3257.
- Meacham, G.C., Lu, Z., King, S., Sorscher, E., Tousson, A., and Cyr, D.M. (1999). The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. *EMBO J.* 18, 1492–1505.
- Meacham, G.C., Patterson, C., Zhang, W., Younger, J.M., and Cyr, D.M. (2001). The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. *Nat. Cell Biol.* 3, 100–105.
- Molinari, M., Calanca, V., Galli, C., Lucca, P., and Paganetti, P. (2003). Role of EDEM in the release of misfolded glycoproteins from the calnexin cycle. *Science* 299, 1397–1400.
- Mumberg, D., Müller, R., and Funk, M. (1995). Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. *Gene* 156, 119–122.
- Oda, Y., Hosokawa, N., Wada, I., and Nagata, K. (2003). EDEM as an acceptor of terminally misfolded glycoproteins released from calnexin. *Science* 299, 1394–1397.
- Palmer, A., Rivett, A.J., Thomson, S., Hendil, K.B., Butcher, G.W., Fuertes, G., and Knecht, E. (1996). Subpopulations of proteasomes in rat liver nuclei, microsomes and cytosol. *Biochem. J.* 316, 401–407.
- Pind, S., Riordan, J.R., and Williams, D.B. (1994). Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. *J. Biol. Chem.* 269, 12784–12788.
- Plempner, R.K., Egner, R., Kuchler, K., and Wolf, D.H. (1998). Endoplasmic reticulum degradation of a mutated ATP-binding cassette transporter Pdr5 proceeds in a concerted action of Sec61 and the proteasome. *J. Biol. Chem.* 273, 32848–32856.
- Plempner, R.K., Bordallo, J., Deak, P.M., Taxis, C., Hitt, R., and Wolf, D.H. (1999). Genetic interactions of Hrd3p and Der3p/Hrd1p with Sec61p suggest a retro-translocation complex mediating protein transport for ER degradation. *J. Cell Sci.* 112, 4123–4134.
- Rabinovich, E., Kerem, A., Fröhlich, K.U., Diamant, N., and Bar-Nun, S. (2002). AAA-ATPase p97/Cdc48p, a cytosolic chaperone required for endoplasmic reticulum-associated protein degradation. *Mol. Cell Biol.* 22, 626–634.
- Riordan, J.R., *et al.* (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 245, 1066–1073.
- Rivett, A.J., Palmer, A., and Knecht, E. (1992). Electron microscopic localization of the multicatalytic proteinase complex in rat liver and in cultured cells. *J. Histochem. Cytochem.* 40, 1165–1172.
- Rose, M.D., Winston, F., and Hieter, P. (1990). *Methods in Yeast Genetics, a Laboratory Course Manual*, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
- Rubenstein, R.C., and Zeitlin, P.L. (2000). Sodium 4-phenylbutyrate down-regulates Hsc 70, implications for intracellular trafficking of DeltaF508-CFTR. *Am. J. Physiol.* 278, C259–C267.
- Rutishauser, J., and Spiess, M. (2002). Endoplasmic reticulum storage diseases, *Swiss Med. Wkly.* 132, 211–222.
- Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989). *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
- Sato, S., Ward, C.L., Krouse, M.E., Wine, J.J., and Kopito, R.R. (1996). Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. *J. Biol. Chem.* 271, 635–638.
- Sikorski, R.S., and Hieter, P. (1989). A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in *Saccharomyces cerevisiae*. *Genetics* 122, 19–27.
- Soni, R., Carmichael, J.P., and Murray, J.A.H. (1993). Parameters affecting lithium acetate-mediated transformation of *Saccharomyces cerevisiae* and development of a rapid and simplified procedure. *Curr. Genet.* 24, 455–459.
- Swanson, R., Locher, M., and Hochstrasser, M. (2001). A conserved ubiquitin ligase of the nuclear envelope/endoplasmic reticulum that functions in both ER-associated and Mat α 2 repressor degradation. *Genes Dev.* 15, 2660–2674.
- Taxis, C., Hitt, R., Park, S.H., Deak, P.M., Kostova, Z., and Wolf, D.H. (2003). Use of modular substrates demonstrates mechanistic diversity and reveals differences in chaperone requirement of ERAD. *J. Biol. Chem.* 278, 35903–35913.
- Tiwari, S., and Weissman, A.M. (2001). Endoplasmic reticulum (ER)-associated degradation of T cell receptor subunits. Involvement of ER-associated ubiquitin-conjugating enzymes (E2s). *J. Biol. Chem.* 276, 16193–16200.
- Wach, A., Brachat, A., Pöhlmann, R., and Philippsen, P. (1994). New heterologous modules for classical or PCR-based gene disruption in *Saccharomyces cerevisiae*. *Yeast* 10, 1793–1808.
- Ward, C.L., and Kopito, R.R. (1994). Intracellular turnover of cystic fibrosis transmembrane conductance regulator. *J. Biol. Chem.* 269, 25710–25718.
- Ward, C.L., Omura, S., and Kopito, R.R. (1995). Degradation of CFTR by the ubiquitin-proteasome pathway. *Cell* 83, 121–127.
- Wiertz, E.J., Tortorella, D., Bogyo, M., Yu, J., Mothes, W., Jones, T.R., Rapoport, T.A., Ploegh, H.L. (1996). Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. *Nature* 384, 432–438.
- Wiertz, E.J., Jones, T.R., Sun, L., Bogyo, M., Geuze, H.J., Ploegh, H.L. (1996). The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. *Cell* 84, 769–779.
- Wigley, W.C., Fabunmi, R.P., Lee, M.G., Marino, C.R., Muallem, S., DeMartino, G.N., and Thomas, P.J. (1999). Dynamic association of proteasomal machinery with the centrosome. *J. Cell Biol.* 145, 481–490.
- Wilhovsky, S., Gardner, R., and Hampton, R. (2000). HRD gene dependence of endoplasmic reticulum-associated degradation. *Mol. Biol. Cell* 11, 1697–1708.
- Yang, Y., Janich, S., Cohn, J.A., and Wilson, J.M. (1993). The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. *Proc. Natl. Acad. Sci. USA* 90, 9480–9484.
- Ye, Y., Meyer, H.H., and Rapoport, T.A. (2001). The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. *Nature* 414, 652–656.
- Yoshida, Y., *et al.* (2002). E3 ubiquitin ligase that recognizes sugar chains. *Nature* 418, 438–442.
- Zhang, Y., Nijbroek, G., Sullivan, M.L., McCracken, A.A., Watkins, S.C., Michaelis, S., and Brodsky, J.L. (2001). Hsp70 molecular chaperone facilitates endoplasmic reticulum-associated protein degradation of cystic fibrosis transmembrane conductance regulator in yeast. *Mol. Biol. Cell* 12, 1303–1314.